GT200900294A - Compuestos amino-heterocíclicos - Google Patents
Compuestos amino-heterocíclicosInfo
- Publication number
- GT200900294A GT200900294A GT200900294A GT200900294A GT200900294A GT 200900294 A GT200900294 A GT 200900294A GT 200900294 A GT200900294 A GT 200900294A GT 200900294 A GT200900294 A GT 200900294A GT 200900294 A GT200900294 A GT 200900294A
- Authority
- GT
- Guatemala
- Prior art keywords
- amino
- heterocyclic compounds
- same
- compounds
- lso
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101100407341 Drosophila melanogaster Pde9 gene Proteins 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
SE PRESENTAN COMPUESTOS INHIBIDORES DE PDE9 DERIVADOS DE AMINO-HETEROCÍCLICOS Y SALES FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LSO COMPUESTOS Y LOS USOS DE LOS MISMOS EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y COGNITIVOS TALES COMO LA ENFERMEDAD DE ALZHEIMER Y ESQUIZOFRENIA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91733307P | 2007-05-11 | 2007-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200900294A true GT200900294A (es) | 2011-08-29 |
Family
ID=39672073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900294A GT200900294A (es) | 2007-05-11 | 2009-11-10 | Compuestos amino-heterocíclicos |
Country Status (44)
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
WO2009068617A1 (en) | 2007-11-30 | 2009-06-04 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
CN105687190A (zh) | 2008-11-19 | 2016-06-22 | 福拉姆医药股份有限公司 | 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍 |
TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
JP5542196B2 (ja) | 2009-03-31 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1−複素環−1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びpde9aモジュレーターとしてのそれらの使用 |
RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP2013507360A (ja) * | 2009-10-08 | 2013-03-04 | イントラ−セルラー・セラピーズ・インコーポレイテッド | ホスホジエステラーゼ1−標的トレーサーおよび方法 |
AU2011256287B2 (en) | 2010-05-17 | 2016-11-10 | Envivo Pharmaceuticals, Inc. | A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
PE20130602A1 (es) | 2010-08-12 | 2013-05-25 | Boehringer Ingelheim Int | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a |
RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
EP2619208B1 (en) * | 2010-09-20 | 2016-11-09 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
US20130040971A1 (en) * | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
ME02394B (me) | 2011-10-07 | 2016-09-20 | Eisai R&D Man Co Ltd | Pirazolohinolinski derivati kao inhibitori pde9 |
MA37958B1 (fr) * | 2011-10-10 | 2018-10-31 | H Lundbeck As | Pde9i ayant un squelette imidazo pyrazinone |
EP3178820B1 (en) * | 2012-01-26 | 2017-12-20 | H. Lundbeck A/S | Pde9- inhibitors with imidazo triazinone backbone |
WO2013142269A1 (en) * | 2012-03-19 | 2013-09-26 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
MD20140130A2 (ro) | 2012-06-29 | 2015-04-30 | Pfizer Inc. | 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2 |
WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
SG11201507733YA (en) | 2013-04-05 | 2015-10-29 | Eisai R&D Man Co Ltd | Pyridinylpyrazoloquinoline compound |
JP5666755B1 (ja) | 2013-04-05 | 2015-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体の塩およびその結晶 |
CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
CA2933767C (en) | 2013-12-17 | 2018-11-06 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
DK3177627T3 (da) | 2014-08-07 | 2019-10-21 | Intra Cellular Therapies Inc | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet |
EP3725789B1 (en) * | 2014-09-17 | 2022-03-09 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JP6608933B2 (ja) * | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
JP6608934B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
WO2016103097A1 (en) | 2014-12-22 | 2016-06-30 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
EP3865484B1 (en) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
EP3349853B1 (en) | 2015-09-15 | 2023-12-20 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
SG10201913986YA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
CN109475556A (zh) | 2016-07-06 | 2019-03-15 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
PL3532064T3 (pl) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych |
MX2019007803A (es) | 2016-12-28 | 2019-08-29 | Dart Neuroscience Llc | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2). |
CN111183140B (zh) * | 2017-05-26 | 2022-12-02 | 伊马拉公司 | 制备和使用pde9抑制剂的方法 |
CA3060030A1 (en) | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
KR102627790B1 (ko) * | 2017-06-01 | 2024-01-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제 |
US11484502B2 (en) | 2017-06-01 | 2022-11-01 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
TW201902898A (zh) | 2017-06-08 | 2019-01-16 | 美商默沙東藥廠 | 吡唑并嘧啶pde9抑制劑 |
KR20200108419A (ko) | 2017-11-27 | 2020-09-18 | 다트 뉴로사이언스, 엘엘씨 | Pde1 억제제로서의 치환된 푸라노피리미딘 화합물 |
WO2019152697A1 (en) | 2018-01-31 | 2019-08-08 | Intra-Cellular Therapies, Inc. | Novel uses |
CN110357888A (zh) * | 2018-04-09 | 2019-10-22 | 南京药捷安康生物科技有限公司 | 杂环磷酸二酯酶抑制剂及其用途 |
BR112021007571A2 (pt) * | 2018-10-21 | 2021-07-27 | Intra-Cellular Therapies, Inc. | novos usos |
KR20200068994A (ko) * | 2018-12-06 | 2020-06-16 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
CN111471059B (zh) | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
WO2023114995A1 (en) * | 2021-12-16 | 2023-06-22 | Pfizer Inc. | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020156277A1 (en) | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
WO2002094790A1 (fr) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Compose heterocyclique condense et son utilisation medicale |
JP2005508978A (ja) * | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Pde9阻害薬によるインスリン抵抗性症候群及び2型糖尿病の治療 |
HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
AU2003253915A1 (en) * | 2002-07-12 | 2004-02-02 | Massachusetts Institute Of Technology | Reconfigurable microphotonics devices via deformable membrane platform |
DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US7051174B2 (en) * | 2002-09-24 | 2006-05-23 | International Business Machines Corporation | Method, system, and program for restoring data in cache |
WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
US7111287B2 (en) * | 2003-01-10 | 2006-09-19 | International Business Machines Corporation | Global processor resource assignment in an assembler |
ATE368666T1 (de) | 2003-03-18 | 2007-08-15 | Jordanian Pharmaceutical Mfg | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren |
CN1894234A (zh) | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
DE10320785A1 (de) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
-
2008
- 2008-05-05 NZ NZ580904A patent/NZ580904A/en unknown
- 2008-05-05 MX MX2009011830A patent/MX2009011830A/es active IP Right Grant
- 2008-05-05 WO PCT/IB2008/001125 patent/WO2008139293A1/en active Application Filing
- 2008-05-05 PT PT08737600T patent/PT2152712E/pt unknown
- 2008-05-05 DK DK08737600.0T patent/DK2152712T3/da active
- 2008-05-05 RS RS20120094A patent/RS52166B/en unknown
- 2008-05-05 ME MEP-2009-330A patent/ME00954B/me unknown
- 2008-05-05 PL PL08737600T patent/PL2152712T3/pl unknown
- 2008-05-05 CN CN2008800242732A patent/CN101687876B/zh active Active
- 2008-05-05 MY MYPI20094735A patent/MY147330A/en unknown
- 2008-05-05 SI SI200830543T patent/SI2152712T1/sl unknown
- 2008-05-05 EA EA200901373A patent/EA016510B1/ru unknown
- 2008-05-05 UA UAA200911482A patent/UA94660C2/ru unknown
- 2008-05-05 EP EP08737600A patent/EP2152712B1/en active Active
- 2008-05-05 KR KR1020097025802A patent/KR101222330B1/ko active IP Right Grant
- 2008-05-05 ES ES08737600T patent/ES2377849T3/es active Active
- 2008-05-05 CA CA2687035A patent/CA2687035C/en active Active
- 2008-05-05 JP JP2010507997A patent/JP4579346B2/ja active Active
- 2008-05-05 GE GEAP200811556A patent/GEP20125405B/en unknown
- 2008-05-05 AU AU2008249750A patent/AU2008249750B2/en active Active
- 2008-05-05 AP AP2009005048A patent/AP2524A/xx active
- 2008-05-05 AT AT08737600T patent/ATE540954T1/de active
- 2008-05-05 BR BRPI0811280A patent/BRPI0811280B8/pt active IP Right Grant
- 2008-05-08 PE PE2008000812A patent/PE20090247A1/es active IP Right Grant
- 2008-05-09 CL CL2008001374A patent/CL2008001374A1/es unknown
- 2008-05-09 AR ARP080101964A patent/AR066502A1/es active IP Right Grant
- 2008-05-09 US US12/118,062 patent/US7964607B2/en active Active
- 2008-05-09 PA PA20088779901A patent/PA8779901A1/es unknown
- 2008-05-09 TW TW097117227A patent/TWI362262B/zh active
-
2009
- 2009-11-05 CR CR11095A patent/CR11095A/es unknown
- 2009-11-05 IL IL201977A patent/IL201977A/en not_active IP Right Cessation
- 2009-11-05 ZA ZA2009/07776A patent/ZA200907776B/en unknown
- 2009-11-06 CU CU2009000184A patent/CU23834B1/es active IP Right Grant
- 2009-11-06 TN TNP2009000471A patent/TN2009000471A1/fr unknown
- 2009-11-09 NI NI200900204A patent/NI200900204A/es unknown
- 2009-11-10 DO DO2009000258A patent/DOP2009000258A/es unknown
- 2009-11-10 CO CO09127785A patent/CO6241157A2/es active IP Right Grant
- 2009-11-10 GT GT200900294A patent/GT200900294A/es unknown
- 2009-11-10 EC EC2009009728A patent/ECSP099728A/es unknown
- 2009-11-11 SV SV2009003411A patent/SV2009003411A/es unknown
- 2009-11-11 MA MA32341A patent/MA31373B1/fr unknown
-
2010
- 2010-09-21 HK HK10108981.2A patent/HK1142595A1/xx unknown
-
2012
- 2012-02-01 HR HR20120105T patent/HRP20120105T1/hr unknown
- 2012-02-06 CY CY20121100125T patent/CY1112332T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200900294A (es) | Compuestos amino-heterocíclicos | |
UY32391A (es) | Compuestos amino-heterocíclicos | |
CL2009000975A1 (es) | Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer. | |
CY1120258T1 (el) | Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος | |
CL2008001921A1 (es) | Compuestos derivados de heterociclos sustituidos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ictus, isquemia cerebral, alzheimer, dolor, entre otras. | |
CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
SV2006002055A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a | |
WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
UY31243A1 (es) | Compuestos de 2-aza-biciclo[2.2.2]octano y usos para los mismos | |
DOP2011000134A (es) | Lactamas como inhibidores de beta secretasa | |
CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
GT201100336A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
CL2011000865A1 (es) | Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras. | |
CL2013002394A1 (es) | Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros. | |
DOP2010000317A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
GT200500348A (es) | Pirazolo[3,4-b]piridinas e indazoles terpeuticos | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
SV2011003839A (es) | Agentes antifungicos |